8-Kfiled July 6, 2021, 7:59 PM ETticker ELOXCIK 0001035354
other materialconfidence highsentiment positivemateriality 0.70
Eloxx updates Phase 2 ELX-02 progress; COO Neil Belloff to depart by Aug 25
Eloxx Pharmaceuticals, Inc.
Neil Belloff, COO and General Counsel, will transition and depart on or before August 25, 2021; will receive base salary and benefits through departure.
Phase 2 study of ELX-02 for cystic fibrosis: sufficient enrollment to assess biological activity; data from first four arms expected Q4 2021.
Fifth treatment arm added to evaluate ELX-02 in combination with Kalydeco (ivacaftor).
No drug-related serious adverse events reported; dose escalation proceeded to top dose level.
Neil Belloff, Chief Operating Officer and General Counsel of the Company, agreed that Mr. Belloff would transition his responsibilities as Chief Operating Officer and General Counsel prior to his departure from the Company on or prior to August 25, 2021.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 1.0
Neil Belloff departed as Chief Operating Officer and General Counsel at Eloxx Pharmaceuticals, Inc..
Action
depart
Role
Chief Operating Officer and General Counsel
Exact text from the filing
Neil Belloff, Chief Operating Officer and General Counsel of the Company, agreed that Mr. Belloff would transition his responsibilities as Chief Operating Officer and General Counsel prior to his departure from the Company on or prior to August 25, 2021.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.